跳至主要内容
临床试验/DRKS00006295
DRKS00006295已完成不适用

ocal ablation of liver and lung metastases in patients with colorectal cancer after failure of first- or later-line systemic chemotherapy – a prospective trial - LOCOMOTIVE

niversitätsklinikum Magdeburg0 个研究点目标入组 152 人开始时间: 2016年4月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
152

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • Histologically confirmed colorectal cancer with liver, lung and / or lymph node metastases
  • progression after chemotherapy
  • No more than 2 members with active disease
  • primary tumor resected, no evidence of local recurrence
  • diameter of the largest liver lesion max. 5 cm, not more than five liver metastases
  • Diameter of the largest lesion 15cm, not more than three liver metastases
  • (Satellite metastases near the target lesion excluded)
  • No more than three lung metastases with a diameter of max. 5cm
  • not more than five lesions up to 3 cm diameter
  • No more than two distant metastases outside the lung and liver (except bone metastases)
  • ECOG performance status = 1
  • Karnofsky Index = 70%

排除标准

  • Cerebral metastasis
  • Symptomatic bone metastasis
  • peritoneal, pleural carcinosis
  • Other malignant diseases
  • Life expectancy <6 months
  • violation of an inclusion criterion

研究者

发起方
niversitätsklinikum Magdeburg

相似试验

ocal ablation of liver and lung metastases in... | 临床试验